Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group

Martin S. Tallman, Haesook T. Kim, Pau Montesinos, Frederick R. Appelbaum, Javier De La Serna, John M. Bennett, Guillermo Deben, Clara D. Bloomfield, Jose Gonzalez, James H. Feusner, Marcos Gonzalez, Robert Gallagher, Jose D. Gonzalez-San Miguel, Richard A. Larson, Gustavo Milone, Elisabeth M. Paietta, Chelo Rayon, Jacob M. Rowe, Concha Rivas, Charles A. SchifferEdo Vellenga, Lois Shepherd, James L. Slack, Peter H. Wiernik, Cheryl L. Willman, Miguel A. Sanz

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Few studies have examined the outcome of large numbers of patients with the microgranular variant (M3V) of acute promyelocytic leukemia (APL) in the all-trans retinoic acid era. Here, the outcome of 155 patients treated with all-trans retinoic acid-based therapy on 3 clinical trials, North American Intergroup protocol I0129 and Programa para el Estudio de la Terapéutica en Hemopatía Maligna protocols LPA96 and LPA99, are reported. The complete remission rate for all 155 patients was 82%, compared with 89% for 748 patients with classical M3 disease. The incidence of the APL differentiation syndrome was 26%, compared with 25% for classical M3 patients, and the early death rate was 13.6% compared with 8.4% for patients with classical M3 morphology. With a median follow-up time among survivors of 7.6 years (range 3.6-14.5), the 5-year overall survival, disease-free survival, and cumulative incidence of relapse for patients with M3V were 70%, 73%, and 24%, respectively. With a median follow-up time among survivors of 7.6 years (range 0.6-14.3), the 5-year overall survival, disease-free survival, and cumulative incidence of relapse among patients with classical M3 morphology were 80% (P = .006 compared with M3V), 81% (P = .07), and 15% (P = .005), respectively. When outcomes were adjusted for the white blood cell count or the relapse risk score, none of these outcomes were significantly different between patients with M3V and classical M3 APL.

Original languageEnglish (US)
Pages (from-to)5650-5659
Number of pages10
JournalBlood
Volume116
Issue number25
DOIs
StatePublished - Dec 16 2010

Fingerprint

Acute Promyelocytic Leukemia
Tretinoin
Blood
Cells
Recurrence
Disease-Free Survival
Survivors
Incidence
Survival
Leukocyte Count
Clinical Trials
Mortality

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group. / Tallman, Martin S.; Kim, Haesook T.; Montesinos, Pau; Appelbaum, Frederick R.; De La Serna, Javier; Bennett, John M.; Deben, Guillermo; Bloomfield, Clara D.; Gonzalez, Jose; Feusner, James H.; Gonzalez, Marcos; Gallagher, Robert; Gonzalez-San Miguel, Jose D.; Larson, Richard A.; Milone, Gustavo; Paietta, Elisabeth M.; Rayon, Chelo; Rowe, Jacob M.; Rivas, Concha; Schiffer, Charles A.; Vellenga, Edo; Shepherd, Lois; Slack, James L.; Wiernik, Peter H.; Willman, Cheryl L.; Sanz, Miguel A.

In: Blood, Vol. 116, No. 25, 16.12.2010, p. 5650-5659.

Research output: Contribution to journalArticle

Tallman, MS, Kim, HT, Montesinos, P, Appelbaum, FR, De La Serna, J, Bennett, JM, Deben, G, Bloomfield, CD, Gonzalez, J, Feusner, JH, Gonzalez, M, Gallagher, R, Gonzalez-San Miguel, JD, Larson, RA, Milone, G, Paietta, EM, Rayon, C, Rowe, JM, Rivas, C, Schiffer, CA, Vellenga, E, Shepherd, L, Slack, JL, Wiernik, PH, Willman, CL & Sanz, MA 2010, 'Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group', Blood, vol. 116, no. 25, pp. 5650-5659. https://doi.org/10.1182/blood-2010-06-288613
Tallman, Martin S. ; Kim, Haesook T. ; Montesinos, Pau ; Appelbaum, Frederick R. ; De La Serna, Javier ; Bennett, John M. ; Deben, Guillermo ; Bloomfield, Clara D. ; Gonzalez, Jose ; Feusner, James H. ; Gonzalez, Marcos ; Gallagher, Robert ; Gonzalez-San Miguel, Jose D. ; Larson, Richard A. ; Milone, Gustavo ; Paietta, Elisabeth M. ; Rayon, Chelo ; Rowe, Jacob M. ; Rivas, Concha ; Schiffer, Charles A. ; Vellenga, Edo ; Shepherd, Lois ; Slack, James L. ; Wiernik, Peter H. ; Willman, Cheryl L. ; Sanz, Miguel A. / Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group. In: Blood. 2010 ; Vol. 116, No. 25. pp. 5650-5659.
@article{c5fbdfa9c44b4bd6a313fa857ab8e7b7,
title = "Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group",
abstract = "Few studies have examined the outcome of large numbers of patients with the microgranular variant (M3V) of acute promyelocytic leukemia (APL) in the all-trans retinoic acid era. Here, the outcome of 155 patients treated with all-trans retinoic acid-based therapy on 3 clinical trials, North American Intergroup protocol I0129 and Programa para el Estudio de la Terap{\'e}utica en Hemopat{\'i}a Maligna protocols LPA96 and LPA99, are reported. The complete remission rate for all 155 patients was 82{\%}, compared with 89{\%} for 748 patients with classical M3 disease. The incidence of the APL differentiation syndrome was 26{\%}, compared with 25{\%} for classical M3 patients, and the early death rate was 13.6{\%} compared with 8.4{\%} for patients with classical M3 morphology. With a median follow-up time among survivors of 7.6 years (range 3.6-14.5), the 5-year overall survival, disease-free survival, and cumulative incidence of relapse for patients with M3V were 70{\%}, 73{\%}, and 24{\%}, respectively. With a median follow-up time among survivors of 7.6 years (range 0.6-14.3), the 5-year overall survival, disease-free survival, and cumulative incidence of relapse among patients with classical M3 morphology were 80{\%} (P = .006 compared with M3V), 81{\%} (P = .07), and 15{\%} (P = .005), respectively. When outcomes were adjusted for the white blood cell count or the relapse risk score, none of these outcomes were significantly different between patients with M3V and classical M3 APL.",
author = "Tallman, {Martin S.} and Kim, {Haesook T.} and Pau Montesinos and Appelbaum, {Frederick R.} and {De La Serna}, Javier and Bennett, {John M.} and Guillermo Deben and Bloomfield, {Clara D.} and Jose Gonzalez and Feusner, {James H.} and Marcos Gonzalez and Robert Gallagher and {Gonzalez-San Miguel}, {Jose D.} and Larson, {Richard A.} and Gustavo Milone and Paietta, {Elisabeth M.} and Chelo Rayon and Rowe, {Jacob M.} and Concha Rivas and Schiffer, {Charles A.} and Edo Vellenga and Lois Shepherd and Slack, {James L.} and Wiernik, {Peter H.} and Willman, {Cheryl L.} and Sanz, {Miguel A.}",
year = "2010",
month = "12",
day = "16",
doi = "10.1182/blood-2010-06-288613",
language = "English (US)",
volume = "116",
pages = "5650--5659",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "25",

}

TY - JOUR

T1 - Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group

AU - Tallman, Martin S.

AU - Kim, Haesook T.

AU - Montesinos, Pau

AU - Appelbaum, Frederick R.

AU - De La Serna, Javier

AU - Bennett, John M.

AU - Deben, Guillermo

AU - Bloomfield, Clara D.

AU - Gonzalez, Jose

AU - Feusner, James H.

AU - Gonzalez, Marcos

AU - Gallagher, Robert

AU - Gonzalez-San Miguel, Jose D.

AU - Larson, Richard A.

AU - Milone, Gustavo

AU - Paietta, Elisabeth M.

AU - Rayon, Chelo

AU - Rowe, Jacob M.

AU - Rivas, Concha

AU - Schiffer, Charles A.

AU - Vellenga, Edo

AU - Shepherd, Lois

AU - Slack, James L.

AU - Wiernik, Peter H.

AU - Willman, Cheryl L.

AU - Sanz, Miguel A.

PY - 2010/12/16

Y1 - 2010/12/16

N2 - Few studies have examined the outcome of large numbers of patients with the microgranular variant (M3V) of acute promyelocytic leukemia (APL) in the all-trans retinoic acid era. Here, the outcome of 155 patients treated with all-trans retinoic acid-based therapy on 3 clinical trials, North American Intergroup protocol I0129 and Programa para el Estudio de la Terapéutica en Hemopatía Maligna protocols LPA96 and LPA99, are reported. The complete remission rate for all 155 patients was 82%, compared with 89% for 748 patients with classical M3 disease. The incidence of the APL differentiation syndrome was 26%, compared with 25% for classical M3 patients, and the early death rate was 13.6% compared with 8.4% for patients with classical M3 morphology. With a median follow-up time among survivors of 7.6 years (range 3.6-14.5), the 5-year overall survival, disease-free survival, and cumulative incidence of relapse for patients with M3V were 70%, 73%, and 24%, respectively. With a median follow-up time among survivors of 7.6 years (range 0.6-14.3), the 5-year overall survival, disease-free survival, and cumulative incidence of relapse among patients with classical M3 morphology were 80% (P = .006 compared with M3V), 81% (P = .07), and 15% (P = .005), respectively. When outcomes were adjusted for the white blood cell count or the relapse risk score, none of these outcomes were significantly different between patients with M3V and classical M3 APL.

AB - Few studies have examined the outcome of large numbers of patients with the microgranular variant (M3V) of acute promyelocytic leukemia (APL) in the all-trans retinoic acid era. Here, the outcome of 155 patients treated with all-trans retinoic acid-based therapy on 3 clinical trials, North American Intergroup protocol I0129 and Programa para el Estudio de la Terapéutica en Hemopatía Maligna protocols LPA96 and LPA99, are reported. The complete remission rate for all 155 patients was 82%, compared with 89% for 748 patients with classical M3 disease. The incidence of the APL differentiation syndrome was 26%, compared with 25% for classical M3 patients, and the early death rate was 13.6% compared with 8.4% for patients with classical M3 morphology. With a median follow-up time among survivors of 7.6 years (range 3.6-14.5), the 5-year overall survival, disease-free survival, and cumulative incidence of relapse for patients with M3V were 70%, 73%, and 24%, respectively. With a median follow-up time among survivors of 7.6 years (range 0.6-14.3), the 5-year overall survival, disease-free survival, and cumulative incidence of relapse among patients with classical M3 morphology were 80% (P = .006 compared with M3V), 81% (P = .07), and 15% (P = .005), respectively. When outcomes were adjusted for the white blood cell count or the relapse risk score, none of these outcomes were significantly different between patients with M3V and classical M3 APL.

UR - http://www.scopus.com/inward/record.url?scp=78650560858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650560858&partnerID=8YFLogxK

U2 - 10.1182/blood-2010-06-288613

DO - 10.1182/blood-2010-06-288613

M3 - Article

C2 - 20858857

AN - SCOPUS:78650560858

VL - 116

SP - 5650

EP - 5659

JO - Blood

JF - Blood

SN - 0006-4971

IS - 25

ER -